What do systematic reviews say?

Low molecular weight heparin vs no thromboprophylaxis

Low‐molecular‐weight heparin probably leads to higher major bleeding compared with no thromboprophylaxis (moderate certainty).

• Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
  RR 1.63 [1.12, 2.35]
  15 studies · 7282 participants
  Moderate

Low molecular weight heparin vs placebo or no prophylaxis

Low molecular weight heparin probably leads to lower deep venous thrombosis compared with no prophylaxis or placebo (moderate certainty).

• Low molecular weight heparin for prevention of venous thromboembolism in patients with lower‐limb immobilization 2017 · Cochrane Headline outcomes only
  OR 0.45 [0.33, 0.61]
  7 studies · 1676 participants
  Moderate

Low molecular weight heparin vs placebo or no prophylaxis

Low molecular weight heparin showed no clear difference in pulmonary embolism compared with no prophylaxis or placebo (low certainty).

• Low molecular weight heparin for prevention of venous thromboembolism in patients with lower‐limb immobilization 2017 · Cochrane Headline outcomes only
  OR 0.5 [0.17, 1.47]
  5 studies · 2517 participants
  Low

Low molecular weight heparin vs placebo or no prophylaxis

Low molecular weight heparin may leads to lower symptomatic venous thromboembolism compared with no prophylaxis or placebo (low certainty).

• Low molecular weight heparin for prevention of venous thromboembolism in patients with lower‐limb immobilization 2017 · Cochrane Headline outcomes only
  OR 0.4 [0.21, 0.76]
  6 studies · 2924 participants
  Low

Low molecular weight heparin vs placebo or no prophylaxis

• Low molecular weight heparin for prevention of venous thromboembolism in patients with lower‐limb immobilization 2017 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 3111 participants
  GRADE not reported

Low molecular weight heparin vs placebo or no prophylaxis

Low molecular weight heparin showed no clear difference in mortality due to other causes compared with no prophylaxis or placebo (low certainty).

• Low molecular weight heparin for prevention of venous thromboembolism in patients with lower‐limb immobilization 2017 · Cochrane Headline outcomes only
  OR 0.33 [0.01, 8.15]
  8 studies · 3111 participants
  Low

Low molecular weight heparin vs placebo or no prophylaxis

Low molecular weight heparin showed no clear difference in adverse outcomes compared with no prophylaxis or placebo (low certainty).

• Low molecular weight heparin for prevention of venous thromboembolism in patients with lower‐limb immobilization 2017 · Cochrane Headline outcomes only
  OR 2.01 [0.83, 4.86]
  8 studies · 3178 participants
  Low

Heparin vs low molecular weight heparin

It is very uncertain whether summary of findings: Heparin changes incidence of hepatic veno‐occlusive disease ( compared with low molecular weight heparin (very low certainty).

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  RR 1.96 [0.8, 4.77]
  1 study · 93 participants
  Very low

Heparin vs low molecular weight heparin

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Heparin vs low molecular weight heparin

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Heparin vs low molecular weight heparin

It is very uncertain whether summary of findings: Heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with low molecular weight heparin (very low certainty).

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  RR 2.94 [0.12, 70.3]
  1 study · 93 participants
  Very low

Heparin vs low molecular weight heparin

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Heparin vs low molecular weight heparin

It is very uncertain whether summary of findings: Heparin changes frequency of adverse events ( compared with low molecular weight heparin (very low certainty).

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  RR 0.84 [0.3, 2.31]
  1 study · 93 participants
  Very low

Summary of findings: Antithrombin III plus heparin vs heparin

It is very uncertain whether summary of findings: Antithrombin III plus heparin changes incidence of hepatic veno‐occlusive disease ( compared with heparin alone (very low certainty).

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  RR 0.13 [0.01, 2.15]
  1 study · 30 participants
  Very low

Summary of findings: Antithrombin III plus heparin vs heparin

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Antithrombin III plus heparin vs heparin

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Antithrombin III plus heparin vs heparin

It is very uncertain whether summary of findings: Antithrombin III plus heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with heparin alone (very low certainty).

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 30 participants
  Very low

Summary of findings: Antithrombin III plus heparin vs heparin

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Antithrombin III plus heparin vs heparin

It is very uncertain whether summary of findings: Antithrombin III plus heparin changes frequency of adverse events ( compared with heparin alone (very low certainty).

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  RR 0.29 [0.04, 2.27]
  1 study · 30 participants
  Very low

Low molecular weight heparin vs no prophylaxis

Low‐molecular‐weight heparin showed no clear difference in PE: assessed by CT arteriography ( compared with no prophylaxis (moderate certainty).

• Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
  RR 1.81 [0.49, 6.65]
  3 studies · 1820 participants
  Moderate